Who has been buying Cell Bio Human Tech stock?

2 distinct insiders have filed 38 disclosed insider purchases in Cell Bio Human Tech (318160), most recently on 2026-05-18. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.

How many insider filings does Cell Bio Human Tech have?

Cell Bio Human Tech has 38 buy-side and 0 sell-side disclosures on record, covering ₩720M ($500K) in total reported value, spanning 2024-02-21 to 2026-05-18.

Where does StockDrifts get Cell Bio Human Tech insider data?

From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.

Do insider buys in Korean stocks predict returns?

Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Cell Bio Human Tech 318160

Company

셀바이오휴먼텍Cell Bio Human Tech

Insiders

Buys

Total Value

₩720M ($500K)

Avg Return

+60.07%

Last Filing

2026-05-18

Cell Bio Human Tech (318160) has 38 disclosed insider purchases and 0 disclosed disposals on record, filed by 2 distinct insiders. Together those filings cover ₩720M ($500K) in reported transaction value. The earliest filing StockDrifts holds for Cell Bio Human Tech is dated 2024-02-21; the most recent is 2026-05-18. All of it is parsed from DART D001/D002 insider disclosures, the official disclosure system operated by the Financial Supervisory Service (Korea). Across these filings the average return since disclosure is +60.07%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

Date	Type	Source	Insider	Position	Shares	Price at filing	Return	Value
2026-05-18	BUY	Market Buy	이권선 Lee Kwon-seon	CEO	5.1K	₩6,120	+2.9%	₩31M ($22K)
2026-05-15	BUY	Market Buy	이권선 Lee Kwon-seon	CEO	7.3K	₩6,280	+0.3%	₩46M ($32K)
2026-04-06	BUY	Market Buy	이권선 Lee Kwon-seon	CEO	1.5K	₩6,700	-6.0%	₩10M ($7K)
2026-04-03	BUY	Market Buy	이권선 Lee Kwon-seon	CEO	1.2K	₩6,710	+16.2%	₩8M ($5K)
2026-04-03	BUY	Market Buy	이권선 Lee Kwon-seon	CEO	1.2K	₩6,710	-6.1%	₩8M ($5K)
2026-04-02	BUY	Market Buy	이권선 Lee Kwon-seon	CEO	680	₩6,770	+15.2%	₩5M ($3K)
2026-04-02	BUY	Market Buy	이권선 Lee Kwon-seon	CEO	680	₩6,770	-6.9%	₩5M ($3K)
2026-04-01	BUY	Market Buy	이권선 Lee Kwon-seon	CEO	3.7K	₩7,060	-10.8%	₩26M ($18K)
2026-04-01	BUY	Market Buy	이권선 Lee Kwon-seon	CEO	3.7K	₩7,060	+10.5%	₩26M ($18K)
2026-03-27	BUY	Market Buy	이권선 Lee Kwon-seon	CEO	1.0K	₩7,300	+0.0%	₩7M ($5K)
2026-03-26	BUY	Market Buy	이권선 Lee Kwon-seon	CEO	3.3K	₩7,050	+3.5%	₩23M ($16K)
2026-03-25	BUY	Market Buy	이권선 Lee Kwon-seon	CEO	2.1K	₩7,170	+1.8%	₩15M ($10K)
2026-03-11	BUY	Market Buy	이권선 Lee Kwon-seon	CEO	800	-	-	-
2026-03-10	BUY	Market Buy	이권선 Lee Kwon-seon	CEO	3.0K	-	-	-
2025-12-30	BUY	자사주상여금	김도완 Dowan Kim	moving	5.4K	₩8,170	-5.8%	₩44M ($31K)
2025-12-30	BUY	자사주상여금	차동균 Cha Dong-gyun	Managing Director	837	₩8,170	-5.8%	₩7M ($5K)
2025-12-30	BUY	자사주상여금	이권선 Lee Kwon-seon	CEO	21.9K	₩8,170	-5.8%	₩179M ($124K)
2025-12-30	BUY	자사주상여금	유정준 Jeongjun Yoo	moving	1.2K	₩8,170	-5.8%	₩9M ($7K)
2025-12-30	BUY	자사주상여금	고현민 Go Hyeon-min	moving	5.4K	₩8,170	-5.8%	₩44M ($31K)
2025-12-30	BUY	자사주상여금	권성원 Seongwon Kwon	Managing Director	6.9K	₩8,170	-5.8%	₩56M ($39K)
2025-11-24	BUY	Market Buy	이권선 Lee Kwon-seon	CEO	350	₩7,310	+5.3%	₩3M ($2K)
2025-11-21	BUY	Market Buy	전영석 Youngseok Jeon	Managing Director	638	₩7,640	+0.8%	₩5M ($3K)
2025-11-19	BUY	Market Buy	이권선 Lee Kwon-seon	CEO	6.9K	₩7,370	+4.5%	₩51M ($35K)
2025-11-12	BUY	Market Buy	전영석 Youngseok Jeon	Managing Director	740	₩10,070	-23.5%	₩7M ($5K)
2025-08-18	BUY	Market Buy	이권선 Lee Kwon-seon	CEO	2.9K	₩8,080	-4.7%	₩24M ($16K)
2025-05-23	BUY	Market Buy	이권선 Lee Kwon-seon	CEO	2.5K	₩5,930	+29.9%	₩15M ($10K)
2025-03-31	BUY	Market Buy	이권선 Lee Kwon-seon	CEO	10.6K	₩4,155	+85.3%	₩44M ($30K)
2025-03-11	BUY	Market Buy	이권선 Lee Kwon-seon	CEO	10.7K	₩4,150	+85.5%	₩44M ($31K)
2025-02-05	BUY	Market Buy	이권선 Lee Kwon-seon	CEO	5.3K	₩3,625	+112.4%	₩19M ($13K)
2024-12-24	BUY	Market Buy	이권선 Lee Kwon-seon	CEO	1.0K	₩3,310	+132.6%	₩3M ($2K)
2024-12-11	BUY	Market Buy	이권선 Lee Kwon-seon	CEO	3.3K	₩3,310	+132.6%	₩11M ($8K)
2024-12-09	BUY	Market Buy	이권선 Lee Kwon-seon	CEO	4.1K	₩2,995	+157.1%	₩12M ($8K)
2024-11-18	BUY	Market Buy	이권선 Lee Kwon-seon	CEO	26.1K	₩3,510	+119.4%	₩91M ($64K)
2024-08-26	BUY	Market Buy	이권선 Lee Kwon-seon	CEO	5.6K	₩3,100	+148.4%	₩17M ($12K)
2024-08-20	BUY	Market Buy	이권선 Lee Kwon-seon	CEO	20.5K	₩3,330	+131.2%	₩68M ($47K)
2024-02-21	BUY	Market Buy	이권선 Lee Kwon-seon	CEO	145	₩3,600	+113.9%	₩522K ($363)
2024-02-21	BUY	Market Buy	이권선 Lee Kwon-seon	CEO	1.0K	₩3,600	+113.9%	₩4M ($3K)
2024-02-21	BUY	Market Buy	이권선 Lee Kwon-seon	CEO	2.0K	₩3,600	+113.9%	₩7M ($5K)
2024-02-21	BUY	Market Buy	이권선 Lee Kwon-seon	CEO	7.0K	₩3,600	+113.9%	₩25M ($18K)
2024-02-21	BUY	Market Buy	이권선 Lee Kwon-seon	CEO	300	₩3,600	+113.9%	₩1M ($750)
2024-02-21	BUY	Market Buy	이권선 Lee Kwon-seon	CEO	1.0K	₩3,600	+113.9%	₩4M ($3K)
2024-02-21	BUY	Market Buy	이권선 Lee Kwon-seon	CEO	5.0K	₩3,600	+113.9%	₩18M ($13K)
2024-02-21	BUY	Market Buy	이권선 Lee Kwon-seon	CEO	4.5K	₩3,600	+113.9%	₩16M ($11K)
2024-02-21	BUY	Market Buy	이권선 Lee Kwon-seon	CEO	5.4K	₩3,600	+113.9%	₩19M ($13K)

Frequently asked questions

Who has been buying Cell Bio Human Tech stock?: 2 distinct insiders have filed 38 disclosed insider purchases in Cell Bio Human Tech (318160), most recently on 2026-05-18. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Cell Bio Human Tech have?: Cell Bio Human Tech has 38 buy-side and 0 sell-side disclosures on record, covering ₩720M ($500K) in total reported value, spanning 2024-02-21 to 2026-05-18.
Where does StockDrifts get Cell Bio Human Tech insider data?: From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.
Do insider buys in Korean stocks predict returns?: Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Source filings

Every trade listed above is disclosed in DART D001/D002 insider disclosures, filed with the Financial Supervisory Service (Korea). View the original DART filings for Cell Bio Human Tech. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.